Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

Biologics target bad bugs

Nature Reviews Drug Discovery volume 9, pages 177–178 (2010)Cite this article

Subjects

Recent deal-making and promising clinical trial results for antibody-based antibacterial agents highlight the potential of such therapeutics to tackle multidrug resistant bacteria.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Andy Extance
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Extance, A. Biologics target bad bugs. Nat Rev Drug Discov 9, 177–178 (2010). https://doi.org/10.1038/nrd3129

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3129

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing